• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在预测人类非强化型胶质瘤的分子亚型方面,扩散加权磁共振成像优于定量T2液体衰减反转恢复序列不匹配。

Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomas.

作者信息

Cho Nicholas S, Sanvito Francesco, Le Viên Lam, Oshima Sonoko, Teraishi Ashley, Yao Jingwen, Telesca Donatello, Raymond Catalina, Pope Whitney B, Nghiemphu Phioanh L, Lai Albert, Salamon Noriko, Cloughesy Timothy F, Ellingson Benjamin M

机构信息

Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.

出版信息

Neuroradiology. 2024 Dec;66(12):2153-2162. doi: 10.1007/s00234-024-03475-z. Epub 2024 Oct 8.

DOI:10.1007/s00234-024-03475-z
PMID:39377927
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11611930/
Abstract

PURPOSE

This study compared the classification performance of normalized apparent diffusion coefficient (nADC) with percentage T2-FLAIR mismatch-volume (%T2FM-volume) for differentiating between IDH-mutant astrocytoma (IDHm-A) and other glioma molecular subtypes.

METHODS

A total of 105 non-enhancing gliomas were studied. T2-FLAIR digital subtraction maps were used to identify T2FM and T2-FLAIR non-mismatch (T2FNM) subregions within tumor volumes of interest (VOIs). Median nADC from the whole tumor, T2FM, and T2NFM subregions and %T2FM-volume were obtained. IDHm-A classification analyses using receiver-operating characteristic curves and multiple logistic regression were performed in addition to exploratory survival analyses.

RESULTS

T2FM subregions had significantly higher nADC than T2FNM subregions within IDHm-A with ≥ 25% T2FM-volume (P < 0.0001). IDHm-A with ≥ 25% T2FM-volume demonstrated significantly higher whole tumor nADC compared to IDHm-A with < 25% T2FM-volume (P < 0.0001), and both IDHm-A subgroups demonstrated significantly higher nADC compared to IDH-mutant oligodendroglioma and IDH-wild-type gliomas (P < 0.05). For classification of IDHm-A vs. other gliomas, the area under curve (AUC) of nADC was significantly greater compared to the AUC of %T2FM-volume (P = 0.01, nADC AUC = 0.848, %T2FM-volume AUC = 0.714) along with greater sensitivity. In exploratory survival analyses within IDHm-A, %T2FM-volume was not associated with overall survival (P = 0.2), but there were non-significant trends for nADC (P = 0.07) and tumor volume (P = 0.051).

CONCLUSION

T2-FLAIR subtraction maps are useful for characterizing IDHm-A imaging characteristics. nADC outperforms %T2FM-volume for classifying IDHm-A amongst non-enhancing gliomas with preserved high specificity and increased sensitivity, which may be related to inherent diffusivity differences regardless of T2FM. In line with previous findings on visual T2FM-sign, quantitative %T2FM-volume may not be prognostic.

摘要

目的

本研究比较了标准化表观扩散系数(nADC)与T2-FLAIR错配体积百分比(%T2FM-体积)在区分异柠檬酸脱氢酶(IDH)突变型星形细胞瘤(IDHm-A)和其他胶质瘤分子亚型方面的分类性能。

方法

共研究了105例无强化的胶质瘤。利用T2-FLAIR数字减法图在感兴趣的肿瘤体积(VOI)内识别T2FM和T2-FLAIR非错配(T2FNM)亚区域。获取整个肿瘤、T2FM和T2NFM亚区域的nADC中位数以及%T2FM-体积。除了探索性生存分析外,还使用受试者工作特征曲线和多元逻辑回归进行IDHm-A分类分析。

结果

在T2FM体积≥25%的IDHm-A中,T2FM亚区域的nADC显著高于T2FNM亚区域(P<0.0001)。与T2FM体积<25%的IDHm-A相比,T2FM体积≥25%的IDHm-A的整个肿瘤nADC显著更高(P<0.0001),并且与IDH突变型少突胶质细胞瘤和IDH野生型胶质瘤相比,这两个IDHm-A亚组的nADC均显著更高(P<0.05)。对于IDHm-A与其他胶质瘤的分类,nADC的曲线下面积(AUC)显著大于%T2FM-体积的AUC(P=0.01,nADC AUC=0.848,%T2FM-体积AUC=0.714),且敏感性更高。在IDHm-A的探索性生存分析中,%T2FM-体积与总生存期无关(P=0.2),但nADC(P=0.07)和肿瘤体积(P=0.051)有不显著的趋势。

结论

T2-FLAIR减法图有助于表征IDHm-A的影像学特征。在对无强化的胶质瘤进行IDHm-A分类时,nADC优于%T2FM-体积,具有较高的特异性和增加的敏感性,这可能与无论T2FM如何的固有扩散率差异有关。与先前关于视觉T2FM信号的研究结果一致,定量的%T2FM-体积可能不具有预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/856a/11611930/ffc724921f3c/234_2024_3475_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/856a/11611930/73b6c44b5956/234_2024_3475_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/856a/11611930/b9b8bce19564/234_2024_3475_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/856a/11611930/ffc724921f3c/234_2024_3475_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/856a/11611930/73b6c44b5956/234_2024_3475_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/856a/11611930/b9b8bce19564/234_2024_3475_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/856a/11611930/ffc724921f3c/234_2024_3475_Fig3_HTML.jpg

相似文献

1
Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomas.在预测人类非强化型胶质瘤的分子亚型方面,扩散加权磁共振成像优于定量T2液体衰减反转恢复序列不匹配。
Neuroradiology. 2024 Dec;66(12):2153-2162. doi: 10.1007/s00234-024-03475-z. Epub 2024 Oct 8.
2
Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.成人低级别胶质瘤患者 T2-FLAIR 不匹配征象与 IDH 突变状态的放射基因组关联:一项更新的系统评价和荟萃分析。
Eur Radiol. 2022 Aug;32(8):5339-5352. doi: 10.1007/s00330-022-08607-8. Epub 2022 Feb 15.
3
Clinicopathological and radiological characteristics of false-positive and false-negative results in T2-FLAIR mismatch sign of IDH-mutated gliomas.IDH 突变型胶质瘤 T2-FLAIR 错配征象中假阳性和假阴性结果的临床病理及影像学特征。
Clin Neurol Neurosurg. 2024 Nov;246:108579. doi: 10.1016/j.clineuro.2024.108579. Epub 2024 Oct 1.
4
Preoperative Diffusion Tensor Imaging and Neurite Dispersion and Density Imaging in Isocitrate Dehydrogenase-Mutant Grade 2 and 3 Gliomas: Definition of Tumor-Related Epilepsy and Predictive Factors of Seizure Outcomes Based on a Single-Center Retrospective Case Series.术前弥散张量成像和神经突弥散与密度成像在异柠檬酸脱氢酶突变的2级和3级胶质瘤中的应用:基于单中心回顾性病例系列对肿瘤相关性癫痫的定义及癫痫预后的预测因素
Neurosurgery. 2025 Jan 29;97(2):361-373. doi: 10.1227/neu.0000000000003365.
5
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.首次就诊时磁共振灌注成像用于鉴别低级别与高级别胶质瘤
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2.
6
Predicting the molecular subtypes of 2021 WHO grade 4 glioma by a multiparametric MRI-based machine learning model.基于多参数磁共振成像的机器学习模型预测2021年世界卫生组织4级胶质瘤的分子亚型
BMC Cancer. 2025 Jul 14;25(1):1171. doi: 10.1186/s12885-025-14529-7.
7
Presence of Fragmented Intratumoral Thrombosed Microvasculature in the Necrotic and Peri-Necrotic Regions on SWI Differentiates IDH Wild-Type Glioblastoma From IDH Mutant Grade 4 Astrocytoma.磁敏感加权成像(SWI)上坏死及坏死周边区域存在瘤内破碎血栓形成的微血管,可将异柠檬酸脱氢酶(IDH)野生型胶质母细胞瘤与IDH突变型4级星形细胞瘤区分开来。
J Magn Reson Imaging. 2025 Jul;62(1):258-270. doi: 10.1002/jmri.29695. Epub 2025 Jan 9.
8
Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy.异柠檬酸脱氢酶(IDH)突变的2级和3级胶质瘤患者延迟放疗或辅助放疗后的特征及预后
Neurology. 2025 Jul;105(1):e213797. doi: 10.1212/WNL.0000000000213797. Epub 2025 Jun 13.
9
Status in Brain Gliomas Can Be Predicted by the Spherical Mean MRI Technique.脑胶质瘤的状态可通过球面均值磁共振成像技术预测。
AJNR Am J Neuroradiol. 2025 Jan 8;46(1):121-128. doi: 10.3174/ajnr.A8432.
10
Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.利用数字减影技术对非增强性弥漫性胶质瘤 T2-FLAIR 不匹配进行定量分析。
AJNR Am J Neuroradiol. 2024 Feb 7;45(2):188-197. doi: 10.3174/ajnr.A8094.

本文引用的文献

1
Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.利用数字减影技术对非增强性弥漫性胶质瘤 T2-FLAIR 不匹配进行定量分析。
AJNR Am J Neuroradiol. 2024 Feb 7;45(2):188-197. doi: 10.3174/ajnr.A8094.
2
Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort.IDH 突变型星形细胞瘤中 T2-FLAIR 不匹配的纵向特征:与 GLASS-NL 队列中的分级、组织病理学及总生存期的关系
Neurooncol Adv. 2023 Nov 9;5(1):vdad149. doi: 10.1093/noajnl/vdad149. eCollection 2023 Jan-Dec.
3
PACS-Integrated Tools for Peritumoral Edema Volumetrics Provide Additional Information to RANO-BM-Based Assessment of Lung Cancer Brain Metastases after Stereotactic Radiotherapy: A Pilot Study.
用于瘤周水肿容积测量的PACS集成工具为立体定向放射治疗后基于RANO-BM的肺癌脑转移评估提供额外信息:一项试点研究。
Cancers (Basel). 2023 Sep 30;15(19):4822. doi: 10.3390/cancers15194822.
4
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.沃拉西尼布治疗 IDH1 或 IDH2 突变型低级别胶质瘤。
N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.
5
The University of California San Francisco Preoperative Diffuse Glioma MRI Dataset.加利福尼亚大学旧金山分校术前弥漫性胶质瘤MRI数据集。
Radiol Artif Intell. 2022 Oct 5;4(6):e220058. doi: 10.1148/ryai.220058. eCollection 2022 Nov.
6
Clinical implementation of artificial intelligence in neuroradiology with development of a novel workflow-efficient picture archiving and communication system-based automated brain tumor segmentation and radiomic feature extraction.随着一种基于新型工作流程高效的图像存档与通信系统的自动化脑肿瘤分割和影像组学特征提取技术的发展,人工智能在神经放射学中的临床应用。
Front Neurosci. 2022 Oct 13;16:860208. doi: 10.3389/fnins.2022.860208. eCollection 2022.
7
A multi-reader comparison of normal-appearing white matter normalization techniques for perfusion and diffusion MRI in brain tumors.多阅读者比较正常表现的脑肿瘤灌注和弥散 MRI 的白质归一化技术。
Neuroradiology. 2023 Mar;65(3):559-568. doi: 10.1007/s00234-022-03072-y. Epub 2022 Oct 27.
8
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.异柠檬酸脱氢酶(IDH)突变型脑胶质瘤:神经肿瘤学会(SNO)关于诊断、管理和未来方向的共识综述。
Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207.
9
Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.常规 MRI 特征可预测成人 2-3 级颅内弥漫性胶质瘤的分子亚型。
Neuroradiology. 2022 Dec;64(12):2295-2305. doi: 10.1007/s00234-022-02975-0. Epub 2022 May 24.
10
T2-fluid-attenuated inversion recovery mismatch sign in lower grade gliomas: correlation with pathological and molecular findings.低级别胶质瘤 T2 液体衰减反转恢复失配征象:与病理和分子发现的相关性。
Brain Tumor Pathol. 2022 Apr;39(2):88-98. doi: 10.1007/s10014-022-00433-6. Epub 2022 Apr 28.